Experimental anti-cancer synthetic molecule targets tumor cell growth and angiogenesis

Jun 18, 2008

A recent study conducted by three French CNRS (Centre National de la Recherche Scientifique) laboratories describes a new candidate anti-cancer drug, named HB-19. In contrast to conventional anti-cancer drugs, HB-19 has a dual mechanism of action by its capacity to target independently both tumor cell growth, as well as tumor angiogenesis (formation of new blood vessels which bring necessary nutrients and oxygen to the tumor mass). The molecular target of HB-19 is nucleolin expressed on the surface of all activated cells, in particular rapidly growing tumor cells and endothelial cells that play a key role in angiogenesis. The results of this work, directed by Ara Hovanessian, are published in the June 18 edition of PLoS ONE.

Nucleolin is one of the major proteins of the nucleus, but it is also expressed on the cell surface where it serves as a binding protein for variety of ligands implicated in cell proliferation, differentiation, adhesion, mitogenesis and angiogenesis. The specific binding of HB-19 to surface-expressed nucleolin leads to internalization of the complex followed by degradation of this multifunctional protein.

Using various in vitro and in vivo experimental models, the authors show that HB-19 is a potent inhibitor of tumor cell growth and angiogenesis. In mice grafted with human breast tumor cells, HB-19 treatment markedly suppresses the progression of tumor development, and in some cases eliminates measurable tumors while displaying no toxicity to normal tissue.

The in vivo antitumoral action of HB-19 in this mouse model (i.e. inhibition of tumor development) is comparable to that of 5-fluorouracil, a drug that is used to treat several types of human cancer. However, 5-fluorouracil has toxic effects on circulating white blood cells whereas HB-19 treatment demonstrated no observable toxicity in this study. Another possible advantage of HB-19 over existing anti-cancer drugs is its reproducible synthesis by conventional techniques to generate a stable product that is readily soluble in physiological solutions.

The direct action of HB-19 on tumor growth and angiogenesis fulfills the criteria for an efficient anticancer drug, since combination therapy targeting both of these events is considered an optimal strategy in cancer management. In view of such dual inhibitory action, reproducible synthesis, high stability, selective tissue retention, and in vivo lack of toxicity, HB-19 may be a promising candidate for evaluation in future clinical trials.

Source: Public Library of Science

Explore further: CHEST lung cancer experts present policy statement to CMS Committee on Coverage

add to favorites email to friend print save as pdf

Related Stories

Will Apple Pay be mobile pay's kick-start?

7 hours ago

If anyone can get us to use our smartphones as wallets, it's Apple. That's what experts think about the recent launch of Apple Pay, the first mobile wallet to work on an iPhone.

Google execs discuss regulation, innovation and bobble-heads

9 hours ago

Eric Schmidt and Jonathan Rosenberg help run Google, one of the world's best-known, most successful - and most controversial - companies. They've just published a new book, "How Google Works," a guide to managing what they ...

Developing the battery of the future

9 hours ago

The search for the next generation of batteries has led researchers at the Canadian Light Source synchrotron to try new methods and materials that could lead to the development of safer, cheaper, more powerful, ...

Gamers' funding fuels meteoric rise of 'Star Citizen'

9 hours ago

Chris Roberts' brain spun out a grand vision: a rich, immersive galaxy; exquisite spaceships traversing between infinite star systems with thousands of computer gamers manning the cockpits, racing, dogfighting and defending ...

Recommended for you

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.